Beyond ASH
Ruben Mesa, MD, FACP
Selection and Sequencing of JAK Inhibitors and Other Emerging Agents for MPNs #BeyondASH21
More from Beyond ASH
Beyond the Congress Panel Discussion Multiple Myeloma #BeyondASH21
Beyond the Congress Panel Discussion Myeloproliferative Neoplasms and Benign Heme #BeyondASH21
Beyond the Congress Panel Discussion Lymphoma #BeyondASH21
Beyond the Congress Panel Discussion Acute Leukemia #BeyondASH21
Beyond the Congress Panel Discussion CLL #BeyondASH21
Selina Luger, MD, FRCPC
Recently Presented Data of Clinical Trials in Patients with AML or ALL #BeyondASH21
Sagar Lonial, MD, FACP
Recently Presented Data of Clinical Trials in Patients with MM #BeyondASH21
Susan O'Brien, MD
; Recently Presented Data of Clinical Trials in Patients with CLL #BeyondASH21
Sonali Smith, MD, FASCO
Best Practices in Treating Aggressive Lymphomas #BeyondASH21
Nitin Jain, MD
Best Strategies for Incorporating Novel Agents, Combinations, and Sequencing of Agents/Regimens in the R/R Setting #BeyondASH21
